Obiefuna Okoli, MD
Infectious Disease · Las Cruces, NMNPI 1457560492
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 533 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Viiv Healthcare Company at 34.8% of the total. Among infectious disease clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 533 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$4K
- AbbVie$2K
- Gilead$2K
- Merck$2K
- Johnson & Johnson$528
- Insmed, Inc.$400
- plus $1K from 15 others
What the payments were for
- Food & beverage$11,82196%
- Education$4764%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 163 | $4,285 |
| AbbVie(2 entities) | 114 | $2,296 |
| Gilead | 96 | $2,127 |
| Merck | 83 | $1,502 |
| Johnson & Johnson(2 entities) | 27 | $528 |
| Insmed, Inc. | 18 | $400 |
| Astellas Pharma US Inc | 9 | $357 |
| Janssen Products, LP | 2 | $215 |
| Janssen Scientific Affairs, LLC | 2 | $153 |
| Ferring Pharmaceuticals Inc. | 5 | $98 |
| La Jolla Pharmaceutical Company | 3 | $81 |
| Paratek Pharmaceuticals, Inc. | 2 | $49 |
| Abiomed | 1 | $46 |
| Napo Pharmaceuticals Inc | 1 | $35 |
| Redhill Biopharma Inc. | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Pfizer | 1 | $18 |
| Grifols USA, LLC | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,298 in reported general payments places this provider in the 90th percentile of 31 infectious disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 399 | $1,668,843 |
| DovatoDolutegravir Sodium/Lamivudine | 231 | $709,973 |
| EpclusaSofosbuvir/Velpatasvir | 16 | $399,693 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 68 | $318,426 |
| TivicayDolutegravir Sodium | 102 | $292,366 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 17 | $252,912 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 54 | $203,199 |
| PrezcobixDarunavir/Cobicistat | 71 | $182,562 |
| DescovyEmtricitabine/Tenofov Alafenam | 79 | $175,456 |
| JulucaDolutegravir/Rilpivirine | 24 | $82,942 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 14 | $60,328 |
| Daptomycin | 62 | $57,700 |
| PifeltroDoravirine | 21 | $34,405 |
| IsentressRaltegravir Potassium | 12 | $23,376 |
| ErtapenemErtapenem Sodium | 41 | $12,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Epclusa, Descovy | $2,127 | $2,243,993494 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Juluca, Triumeq | $4,285 | $1,145,610371 claims |
| Janssen Products, LPSymtuza | $215 | $318,42668 claims |
| Insmed, Inc.Arikayce | $400 | $252,91217 claims |
| Johnson & JohnsonPrezcobix | $528 | $182,56271 claims |
| MerckPifeltro, Isentress | $1,502 | $57,78133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 31 infectious disease providers in New Mexico.
Other infectious disease in Las Cruces
- Cathy PettiAlbuquerque$29K
- Joel GallantSanta Fe$18K
- Jeffrey RossAlbuquerque$5K
- Thomas RobertsAlbuquerque$5K
- Mohamed Al KatebAlbuquerque$2K
- Felix CernaAlbuquerque$2K
- Jorge Soria MoncadaAlbuquerque$2K
- David StrykerAlbuquerque$2K
- Christine BoehringerAlbuquerque$1K
- Robert ParsonsAlbuquerque$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.